RECENT COMMENTS

Constantinos Zambirinis (Thyroid cancer management): As you mentioned above, differentiated thyroid cancer is followed after treatment with the thyroglob [...]   »Read more

Dr Lobna Sedky (Serigne Magueye Gueye): Within Africa,the scope of cancer differs even between various geographic regions. Being an oncologi [...]   »Read more

DR PUSHKAL DWIVEDI (World Cancer Declaration): I FULLY AGREE!   »Read more

Dr Olayinka O Adegbehingbe (World Cancer Declaration): Dear Prof Franco Cavalli, The World Cancer Declaration is great and impacts in developing countries [...]   »Read more

Tung Dinh Nguyen (World Cancer Declaration): Dear Dr F Cavalli, I have had a lot of chance to see Dr F. Cacalli In Hue, Vietnam. The World Ca [...]   »Read more

 

Article type: Editorial

Keywords: Herceptin, breast cancer, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

Hope or hype?

Decades of experience have taught us to guard against the temptation to trumpet early impressive results as breakthroughs. Yet some of the comments over the promising results from trials testing Herceptin (trastuzumab) in early-stage breast cancer raise questions

» Kathy Redmond


To read the complete article please click on the pdf icon
 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

E-eso
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
E-aso
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
 
ECPC
ECPC
Europa Donna
Europa
Donna
Europa Uomo
Europa
Uomo
EONS
EONS
SIOG
SIOG
The challenge Fund
The
Challenge
Fund
Seno network
SenoNetwork
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, GlaxoSmithKline, Merck and Novartis.